NEW YORK (GenomeWeb) – Qiagen said on Thursday that it is partnering with Freenome to develop next-generation sequencing-based companion diagnostics for immuno-oncology.
Under the agreement the companies will pair Freenome's artificial intelligence genomics platform with various Qiagen molecular analysis platforms and co-market the technologies to pharmaceutical companies.